Which proton pump inhibitor can be used in a child with Child‑Pugh class C hepatic impairment?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 31, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Which PPI Can Be Used in Child-Pugh Score C?

No proton pump inhibitor should be routinely used in patients with Child-Pugh C cirrhosis, as these patients should generally avoid PPIs due to lack of safety data and the high risk of complications in this population. However, if acid suppression is absolutely necessary for a life-threatening indication (such as active bleeding from erosive esophagitis), omeprazole at a maximum dose of 20 mg daily can be considered with extreme caution, as this is the only PPI specifically mentioned in hepatitis C treatment guidelines in the context of severe hepatic impairment 1.

Key Evidence and Reasoning

Hepatic Impairment and PPIs

The available guideline evidence addresses PPIs primarily in the context of drug-drug interactions with hepatitis C antivirals, not as standalone therapy for acid suppression in Child-Pugh C patients. The EASL guidelines mention that when sofosbuvir/velpatasvir is used, PPIs should generally be avoided, but if necessary, the regimen should be given with food 4 hours before a PPI "at maximum dose comparable to omeprazole 20 mg" 1. This suggests omeprazole 20 mg has been studied to some degree in patients with severe liver disease, though not specifically for safety in Child-Pugh C.

Why Child-Pugh C Patients Should Avoid PPIs

The fundamental issue is that patients with Child-Pugh C cirrhosis should not be receiving most medications that undergo hepatic metabolism 2. The EASL guidelines explicitly state that patients with Child-Pugh C cirrhosis should not be treated with standard antiviral regimens "due to a high risk of life-threatening complications" 2. This principle extends to PPIs, which undergo hepatic metabolism.

Recent research confirms that inappropriate PPI use is particularly common in Child-Pugh C patients 3. A 2025 cross-sectional study found that Child-Pugh C classification was an independent predictor of inappropriate PPI use, with 53.6% of cirrhotic patients receiving PPIs inappropriately 3.

Practical Algorithm for PPI Use in Child-Pugh C

Step 1: Question the indication

  • Is there documented erosive esophagitis on endoscopy?
  • Is there active upper GI bleeding requiring acid suppression?
  • If the answer is no to both, do not prescribe a PPI 3

Step 2: Consider alternatives

  • H2-receptor antagonists (famotidine, ranitidine) may be safer alternatives as they have less hepatic metabolism
  • Non-pharmacologic measures (head of bed elevation, dietary modifications)

Step 3: If PPI is absolutely necessary

  • Use omeprazole 20 mg once daily (the lowest effective dose mentioned in guidelines) 1
  • Limit duration to the shortest possible course
  • Monitor closely for hepatic decompensation

Step 4: Avoid these PPIs entirely

  • No specific data exists for esomeprazole, lansoprazole, rabeprazole, or pantoprazole in Child-Pugh C
  • Pantoprazole, despite being the most commonly prescribed PPI in cirrhosis (55.7%), has no safety data in Child-Pugh C 3

Critical Pitfalls to Avoid

  1. Do not prescribe PPIs for stress ulcer prophylaxis in non-ICU Child-Pugh C patients - This was identified as a major cause of inappropriate use (15.86% of cases) 3

  2. Do not continue PPIs for portal hypertensive gastropathy (PHG) or variceal bleeding prevention - This accounted for 16.42% of inappropriate use 3. PPIs do not prevent variceal bleeding.

  3. Do not extend PPI therapy beyond 2-4 weeks post-endoscopic band ligation - Prolonged use post-EBL was the leading cause of inappropriate PPI prescribing (29.1%) 3

  4. Do not prescribe PPIs for functional dyspepsia in Child-Pugh C - This represented 21.46% of inappropriate use 3

Safety Concerns Specific to Advanced Cirrhosis

While recent data suggests PPIs may not increase infection risk in acute-on-chronic liver failure (ACLF) 4, this does not mean they are safe in stable Child-Pugh C patients. The immunosuppression, altered gut barrier, and risk of spontaneous bacterial peritonitis in Child-Pugh C patients warrant extreme caution with any medication that alters gastric pH and gut microbiome 4.

The bottom line: In Child-Pugh C cirrhosis, the default should be to avoid PPIs entirely unless there is a compelling, documented indication that cannot be managed with alternatives. If absolutely required, omeprazole 20 mg daily is the only option with any mention in the literature, and even this should be used for the shortest duration possible.

References

Related Questions

What are the appropriate indications for using a proton‑pump inhibitor in patients with chronic liver disease?
How are proton‑pump inhibitors metabolized by the liver, and what dosing adjustments are recommended for patients with hepatic impairment?
What is the recommended proton pump inhibitor (PPI) dosing and duration for a 13-year-old child with gastro‑esophageal reflux disease, including erosive esophagitis?
Through what mechanism do proton pump inhibitors reduce gastric emptying?
Which proton pump inhibitors (PPIs) are recommended for children with gastro‑esophageal reflux disease, and what are the appropriate dosing regimens?
Which hormones are elevated during the follicular phase and which hormones are elevated during the luteal phase of the menstrual cycle?
Should patients with intracerebral hemorrhage receive seizure prophylaxis, and what regimen is recommended for high‑risk cases?
Does cefdinir provide adequate coverage for the bacteria commonly involved in a dental abscess?
Is a twice‑weekly subcutaneous testosterone regimen of 70 mg on Sunday morning and 70 mg on Wednesday morning a normal schedule?
When should I measure serum testosterone level if I am giving testosterone injections twice weekly (e.g., 70 mg subcutaneously on Sunday and Wednesday)?
How should I counsel a runner with a 12‑mm os trigonum causing posterior ankle impingement, and is referral to a sports‑medicine or foot‑ankle orthopaedic surgeon indicated?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.